Ombitasvir; Paritaprevir; Ritonavir Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

It is formulated by 1 pharmaceutical company such as ABBVIE. It is marketed under 2 brand names, including TECHNIVIE, VIEKIRA XR. Available in 2 different strengths, such as 12.5MG;75MG;50MG, EQ 200MG BASE;8.33MG;50MG;33.33MG, and administered through 2 routes including TABLET;ORAL, TABLET, EXTENDED RELEASE;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"87944","ingredient":"OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"0be64e323b3f4498bf5b","publication_number":"US8268349B2","cleaned_patent_number":"8268349","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-02-25","publication_date":"2012-09-18","legal_status":"Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362"} US8268349B2 18 Sep, 2012 Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362 25 Feb, 2025
{"application_id":"87886","ingredient":"OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"0be64e323b3f4498bf5b","publication_number":"US8399015B2","cleaned_patent_number":"8399015","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-02-25","publication_date":"2013-03-19","legal_status":"Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362"} US8399015B2 19 Mar, 2013 Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362 25 Feb, 2025
{"application_id":"87648","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"9a97fa1ca80e4e34a03d","publication_number":"US8501238B2","cleaned_patent_number":"8501238","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-09-17","publication_date":"2013-08-06","legal_status":"Granted"} US8501238B2 Molecular Formulation 06 Aug, 2013 Granted 17 Sep, 2028
{"application_id":"87691","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"9a97fa1ca80e4e34a03d","publication_number":"US9139536B2","cleaned_patent_number":"9139536","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-11-09","publication_date":"2015-09-22","legal_status":"Granted"} US9139536B2 22 Sep, 2015 Granted 09 Nov, 2028
{"application_id":"87690","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"9a97fa1ca80e4e34a03d","publication_number":"US8188104B2","cleaned_patent_number":"8188104","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-05-17","publication_date":"2012-05-29","legal_status":"Granted"} US8188104B2 Molecular Formulation 29 May, 2012 Granted 17 May, 2029
{"application_id":"87703","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"317d3135be424acc961f","publication_number":"US8642538B2","cleaned_patent_number":"8642538","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-09-10","publication_date":"2014-02-04","legal_status":"Granted"} US8642538B2 Molecular Formulation 04 Feb, 2014 Granted 10 Sep, 2029
{"application_id":"64808","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"c6ce776a65934e66b729","publication_number":"US9006387B2","cleaned_patent_number":"9006387","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-06-10","publication_date":"2015-04-14","legal_status":"Granted"} US9006387B2 14 Apr, 2015 Granted 10 Jun, 2030
{"application_id":"87582","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"4499aeda0c704f5eb99e","publication_number":"US9044480B1","cleaned_patent_number":"9044480","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-04-10","publication_date":"2015-06-02","legal_status":"Granted"} US9044480B2 02 Jun, 2015 Granted 10 Apr, 2031
{"application_id":"64803","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"c6ce776a65934e66b729","publication_number":"US8686026B2","cleaned_patent_number":"8686026","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-06-09","publication_date":"2014-04-01","legal_status":"Granted"} US8686026B2 Formulation 01 Apr, 2014 Granted 09 Jun, 2031
{"application_id":"87801","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"317d3135be424acc961f","publication_number":"US8420596B2","cleaned_patent_number":"8420596","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-10","publication_date":"2013-04-16","legal_status":"Granted"} US8420596B2 16 Apr, 2013 Granted 10 Oct, 2031
{"application_id":"64804","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"TECHNIVIE","family_id":"c6ce776a65934e66b729","publication_number":"US8691938B2","cleaned_patent_number":"8691938","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-04-13","publication_date":"2014-04-08","legal_status":"Granted"} US8691938B2 Molecular Formulation 08 Apr, 2014 Granted 13 Apr, 2032
{"application_id":"87881","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"c8d9b5194e6946e4a21e","publication_number":"US10201584B1","cleaned_patent_number":"10201584","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-05-17","publication_date":"2019-02-12","legal_status":"Granted"} US10201584B2 12 Feb, 2019 Granted 17 May, 2032
{"application_id":"87882","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"c8d9b5194e6946e4a21e","publication_number":"US10201541B1","cleaned_patent_number":"10201541","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-05-17","publication_date":"2019-02-12","legal_status":"Patented case"} US10201541B2 Formulation 12 Feb, 2019 Patented case 17 May, 2032
{"application_id":"87811","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"d2944ffcd658423cbd59","publication_number":"US8685984B2","cleaned_patent_number":"8685984","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-04","publication_date":"2014-04-01","legal_status":"Granted"} US8685984B2 01 Apr, 2014 Granted 04 Sep, 2032
{"application_id":"87585","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"e2771a120d6745628f33","publication_number":"US8466159B2","cleaned_patent_number":"8466159","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-04","publication_date":"2013-06-18","legal_status":"Granted"} US8466159B2 18 Jun, 2013 Granted 04 Sep, 2032
{"application_id":"87632","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"e2771a120d6745628f33","publication_number":"US8680106B2","cleaned_patent_number":"8680106","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-04","publication_date":"2014-03-25","legal_status":"Granted"} US8680106B2 25 Mar, 2014 Granted 04 Sep, 2032
{"application_id":"87858","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"d2944ffcd658423cbd59","publication_number":"US8492386B2","cleaned_patent_number":"8492386","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-04","publication_date":"2013-07-23","legal_status":"Granted"} US8492386B2 23 Jul, 2013 Granted 04 Sep, 2032
{"application_id":"87698","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"1f9d6e9e77ab4179b88f","publication_number":"US9744170B2","cleaned_patent_number":"9744170","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-02","publication_date":"2017-08-29","legal_status":"Patented case"} US9744170B2 Formulation 29 Aug, 2017 Patented case 02 Jan, 2035
{"application_id":"87695","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"1f9d6e9e77ab4179b88f","publication_number":"US9333204B2","cleaned_patent_number":"9333204","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-02","publication_date":"2016-05-10","legal_status":"Granted"} US9333204B2 Formulation 10 May, 2016 Granted 02 Jan, 2035
{"application_id":"87699","ingredient":"DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR","trade_name":"VIEKIRA XR","family_id":"1f9d6e9e77ab4179b88f","publication_number":"US10105365B2","cleaned_patent_number":"10105365","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-02","publication_date":"2018-10-23","legal_status":"Granted"} US10105365B2 Formulation 23 Oct, 2018 Granted 02 Jan, 2035

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Ombitasvir; Paritaprevir; Ritonavir

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.